Navigation Links
FDA Approves 4 Swine Flu Vaccines
Date:9/15/2009

inical studies of the H1N1 vaccine are continuing to determine the optimal dose in children, with the results expected shortly, the FDA said.

The four vaccines are made by CSL Limited, MedImmune LLC, Novartis Vaccines and Diagnostics Limited, and Sanofi Pasteur Inc. All four firms manufacture the H1N1 vaccines using the same processes, and have a proven safety record producing seasonal influenza vaccines, according to the FDA.

The preliminary trials of the vaccine has shown it to be well-tolerated, with side effects typical of seasonal flu vaccines. Those side effects include soreness at the injection site, as well as possible mild fever, body aches, and fatigue for a few days after the inoculation. For the nasal spray vaccine, the most common side effects include runny nose or nasal congestion for all ages, sore throats in adults, and -- in children 2 to 6 years old -- fever, the FDA said.

The FDA stressed that the H1N1 vaccine won't protect against regular seasonal flu. That's why people are urged to get their seasonal flu shots now, even though the H1N1 virus accounts for about 98 percent of the flu circulating right now in the United States.

"We think the novel strain of H1N1 is going to be widely circulating, but as the season progresses we may see other seasonal flu viruses emerge and start to spread. So it makes sense that people get their seasonal flu shot, because we could very well see those strains of influenza circulate widely as our season progresses," said Tom Skinner, a spokesman for the U.S. Centers for Disease Control and Prevention.

On Monday, several news studies suggested that people infected with swine flu seem to be contagious longer than patients with ordinary seasonal flu.

But it's not clear what impact the findings will have on health-care experts' recommendations to combat the H1N1 swine flu, since the virus continues to produce relatively mild infections in most people and reco
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3 4

Related medicine news :

1. FDA Approves Valcyte(R) (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants
2. FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria
3. Health Canada Approves Abbotts XIENCE V(R) Drug Eluting Stent
4. First 5 California Approves $81.4 Million Contribution to Help Restore Healthy Families Programs Viability
5. Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain
6. FDA Approves New 3000 IU Vial Size for Kogenate(R) FS, antihemophilic factor (recombinant)
7. FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia
8. FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
9. House Committee Approves Amendment Eliminating Cost-Sharing for Medicaid Preventive Services
10. FDA Approves TYVASO (Treprostinil) Inhalation Solution for the Treatment of Pulmonary Arterial Hypertension
11. FDA Approves Sculptra(R)Aesthetic, a Facial Injectable for Correction of Nasolabial Folds and Other Facial Wrinkles
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Approves 4 Swine Flu Vaccines 
(Date:8/20/2014)... August is Children’s Eye Health and ... about eye health and safety for their children and ... condition that must be checked for, according to Sharon ... Water radio show, is pediatric dry eye. With computer ... eye is becoming a very real concern to ophthalmologists. ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Biosimilars, ... that are approved through an abbreviated process, could ... issue of Atlantic Information Services, Inc.’s (AIS) Specialty ... this segment, including the Food and Drug Administration’s ... first step towards approval. , Drugmaker Sandoz said ...
(Date:8/20/2014)... August 20, 2014 Ticketability.com ... public at fair prices. The well-known medium has been ... is now touring in 19 cities, with tickets becoming ... television personality will visit are Albany, Baltimore, Trenton, Erie, ... Albuquerque, Beverly Hills and San Diego. The medium’s fans ...
(Date:8/20/2014)... often have difficulty falling asleep and staying asleep, and ... individuals with Alzheimer,s disease, this common and troubling symptom ... to nighttime confusion and wandering. , Now, a study ... (BIDMC) and the University of Toronto/Sunnybrook Health Sciences Center ... Reported online today in the journal Brain , ...
(Date:8/20/2014)... At this moment, Ebola is causing horrific, ... the root cause of the virus and other problems Africans ... nonprofit organization Books For Africa to provide copies of his ... Live the Life of Their Dreams, to those who could ... with the tools they need to make the leap to ...
Breaking Medicine News(10 mins):Health News:August is Children’s Eye Health Month, Exams Must Check for Pediatric Dry Eye 2Health News:August is Children’s Eye Health Month, Exams Must Check for Pediatric Dry Eye 3Health News:AIS Newsletter Tracks Latest Developments in Biosimilars Market as FDA Accepts First Application 2Health News:AIS Newsletter Tracks Latest Developments in Biosimilars Market as FDA Accepts First Application 3Health News:Theresa Caputo Tour Tickets for Sale at Ticketability.com Cause a Buying Frenzy Among Customers Over Their Offering of Deeply Discounted Seats 2Health News:Research helps explain why elderly have trouble sleeping 2Health News:Research helps explain why elderly have trouble sleeping 3Health News:Ebola, Poverty, and a Partnership for Africa—How Everyone Can Help 2Health News:Ebola, Poverty, and a Partnership for Africa—How Everyone Can Help 3
... heart attacks, strokes among those without established heart ... An analysis of studies supports a growing belief ... be expanded to include healthy people without established ... 10 trials involving more than 70,000 participants found ...
... Services to Focus on the Delivery of Early Stage Services -, ... July 1 /PRNewswire-FirstCall/ - MDS Inc. (TSX: MDS; NYSE: ... global life sciences markets, today announced that it has completed the ... Under the terms of the agreement, INC Research, a leading global ...
... new treatments eliminate risks of traditional procedures , , ROSEMONT, ... respond successfully to initial treatment may have a second chance at ... area, according to a study published in the July 2009 issue ... Academy of Orthopaedic Surgeons (JAAOS). ...
... Netherlands: Survivors of childhood cancer run particular risks ... 25th annual conference of the European Society of ... July). Dr. Sharon Lie Fong, of the Department ... Centre, Rotterdam, The Netherlands, said that, although such ...
... , AstraZeneca Patent Shown to be Invalid Based on New ... , , NEW YORK, July 1 Article ... validity of AstraZeneca,s Crestor U.S. drug patent, in closing out ... premier validity evidence which can show the Crestor patent to ...
... ... Center Leverages Fusionfx Solution Suite to Improve Patient Experience , ... Scottsdale, AZ (Vocus) June ... a nationally recognized non-profit provider of integrated health services, has chosen the Fusionfx ...
Cached Medicine News:Health News:Study Supports Wider Use of Statins 2Health News:Study Supports Wider Use of Statins 3Health News:MDS Inc. Completes Divestiture of MDS Pharma Services Phase II-IV Operations 2Health News:Emerging Techniques Put a New Twist on Ankle Repair 2Health News:Emerging Techniques Put a New Twist on Ankle Repair 3Health News:Cancer survivors at greater risk of birth complications; special monitoring needed 2Health News:Crestor Patent Invalidity Evidence Uncovered By Article One Partners Community 2Health News:Crestor Patent Invalidity Evidence Uncovered By Article One Partners Community 3Health News:Crestor Patent Invalidity Evidence Uncovered By Article One Partners Community 4Health News:Virginia Mason Signs with Carefx to Implement Fusionfx Solution Suite 2Health News:Virginia Mason Signs with Carefx to Implement Fusionfx Solution Suite 3
(Date:8/19/2014)... KIRKLAND, Wash. , Aug. 19, 2014 ... solutions, will be exhibiting at the 2014 NPPA Summer ... The company will be showcasing its 340B software products ... leader in 340B splitting solutions, supplying over 400 customers ... a range of 340B solutions including its latest solution, ...
(Date:8/19/2014)... YORK , Aug. 19, 2014 /PRNewswire-iReach/ -- ChemImage ... will present a scientific poster describing an innovative diagnostic ... SPEC 2014: Shedding New Light on Disease (SPEC) conference ... Dr. Treado,s poster entitled, "Development of in vitro ... Imaging" will be discussed during the conference poster session ...
(Date:8/19/2014)... , Aug. 19, 2014  Tokyo-based Atonarp Inc. ... funding round led by Walden Riverwood Ventures with ... development of Atonarp,s Smart Spectrometer technology platform, which ... company has targeted the oil & gas and ... "We are excited to partner with Atonarp in ...
Breaking Medicine Technology:Talyst Exhibits at the NPPA Summer Conference 2ChemImage Scientists Present Latest Developments for in vitro Detection of Colorectal Cancer Using Raman Molecular Imaging (RMI) at International Conference Focused on Biomedical Applications of Raman Spectroscopy 2Atonarp Inc. Raises $8M Series A Round Led by Walden Riverwood Ventures 2
... China Botanic Pharmaceutical Inc. (AMEX: CBP ) ... distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ... the Company,s new Chief Financial Officer ("CFO") on December ... over 10 years with key positions in finance, audit, ...
... Calif. and LUXEMBOURG, Dec. 16, 2010 WaferGen Biosystems, ... leading developer of state-of-the-art genomic analysis systems, and the ... to establish a strategic relationship that will expand the ... Europe and advance personalized medicine.   The ...
Cached Medicine Technology:China Botanic Appoints David Dong as New Chief Financial Officer 2China Botanic Appoints David Dong as New Chief Financial Officer 3WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 2WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 3WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 4WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 5
Inquire...
Inquire...
... Optimal for Subcellular Fractionation, ... x g (30,000 rpm) with ... from 0.25 up to 85 ... 2° C to 40° C ...
... Fractionation, Proteins and Viruses • ... with fixed-angle rotor • Spin ... 85 mL • Operating temperature ... C • Rotors certified by ...
Medicine Products: